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ABSTRACT
Background
Dysfunction of the immune system has been documented in many types of cancers. The
precise nature and molecular basis of immune dysfunction in the cancer state are not well
defined.
Methods and Findings
To gain insights into the molecular mechanisms of immune dysfunction in cancer, gene
expression profiles of pure sorted peripheral blood lymphocytes from 12 patients with
melanoma were compared to 12 healthy controls. Of 25 significantly altered genes in T cells
and B cells from melanoma patients, 17 are interferon (IFN)-stimulated genes. These microarray
findings were further confirmed by quantitative PCR and functional responses to IFNs. The
median percentage of lymphocytes that phosphorylate STAT1 in response to interferon-a was
significantly reduced (D ¼ 16.8%; 95% confidence interval, 0.98% to 33.35%) in melanoma
patients (n¼9) compared to healthy controls (n¼9) in Phosflow analysis. The Phosflow results
also identified two subgroups of patients with melanoma: IFN-responsive (33%) and low-IFN-
response (66%). The defect in IFN signaling in the melanoma patient group as a whole was
partially overcome at the level of expression of IFN-stimulated genes by prolonged stimulation
with the high concentration of IFN-a that is achievable only in IFN therapy used in melanoma.
The lowest responders to IFN-a in the Phosflow assay also showed the lowest gene expression
in response to IFN-a. Finally, T cells from low-IFN-response patients exhibited functional
abnormalities, including decreased expression of activation markers CD69, CD25, and CD71;
TH1 cytokines interleukin-2, IFN-c, and tumor necrosis factor a, and reduced survival following
stimulation with anti-CD3/CD28 antibodies compared to controls.
Conclusions
Defects in interferon signaling represent novel, dominant mechanisms of immune
dysfunction in cancer. These findings may be used to design therapies to counteract immune
dysfunction in melanoma and to improve cancer immunotherapy.
The Editors’ Summary of this article follows the references.
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Cancer inhibits the immune system by various cellular and
molecular mechanisms. Dysfunction of the immune system
arises during the early stages of cancer and throughout
progression to metastatic disease [1]. CD8 T lymphocytes
speciﬁc for tumor-associated antigens (TAAs) are often
present in the blood of cancer patients and accumulate in
tumor-draining lymph nodes and in primary and metastatic
tumor sites [2]. While TAA-speciﬁc CD8 T cells are elicited in
the majority of patients receiving current peptide vaccines
and other immunotherapies, they do not effectively control
or eradicate tumors, and the presence or magnitude of these
responses does not reliably correlate with clinical outcome
[3]. Such cells may be speciﬁcally driven into apoptosis [4,5]
or rendered nonresponsive (anergic) in vivo, preventing
cytolytic responses against tumor cells and appropriate
activation to stimuli. Indeed, dysfunction of TAA-speciﬁc
CD8 T cells has been shown in melanoma and other cancers
[2,6]. TAA-speciﬁc CD4 T cells have also been identiﬁed and
are thought to help the function, persistence, and magnitude
of antigen-speciﬁc CD8 T cell responses [7,8]. Current
immunotherapeutic strategies are subject to the immuno-
suppressive effects of cancer and regulatory T cells, which
likely contribute to their lack of success thus far [9–13]. The
precise nature and molecular basis of immune dysfunction in
the cancer state are not well deﬁned. Elucidation of the
mechanisms of immune dysfunction in cancer will allow
rational design of strategies to reverse existing immune
dysfunction and normalization of lymphocyte populations to
improve the endogenous immune responses to cancer and to
improve the efﬁcacy of cancer immunotherapy.
We focused on the major lymphocyte populations that may
be involved in antitumor responses and negatively impacted
by cancer, speciﬁcally CD8 T cells, CD4 T cells, B cells, and
CD56dim natural killer (NK) cells from patients with
metastatic melanoma. Inhibition of these lymphocyte pop-
ulations in cancer would allow tumor progression and hinder
immunotherapeutic approaches. The gene expression pro-
ﬁles of these cells were studied using new generation DNA
microarrays (Agilent Human 1A v2). While many DNA
microarray studies use heterogeneous cell populations, such
as tumor or peripheral blood mononuclear cell (PBMC)
samples, our study utilized pure cell subsets, stringently
sorted by ﬂow cytometry, to enable precise analysis of the
cells of interest. The aim of our study was to use the gene
expression proﬁles of lymphocyte subsets from melanoma
patients to elucidate aspects and mechanisms of immune
dysfunction in cancer. These ﬁndings were conﬁrmed by
quantitative real-time PCR and further investigated via
several novel assays including Phosﬂow analysis.
Methods
Patient and Healthy Donor Samples
PBMCs were obtained from patients with American Joint
Committee on Cancer stage IV melanoma (University of
Southern California Norris Cancer Center, Los Angeles,
California), prior to biological or chemotherapy, with
informed consent. All patients had visceral disease and all
patients relapsed. PBMCs were also obtained from healthy
donors that were age- and gender-matched to the patients
(Stanford Blood Center, Stanford, California). PBMCs were
cryopreserved in 90% NCS–10% DMSO. The experiments
were approved by the Institutional Review Boards of
University of Southern California Norris Cancer Center and
Stanford University.
Sorting of PBMCs into Lymphocyte Subsets
Cryopreserved PBMCs were thawed, extensively washed,
and rested overnight in RPMI 1640 containing 10% FBS.
PBMCs were washed and stained with antibodies to CD56,
CD16, CD8, CD3, CD4, and CD19 (BD Biosciences, http://www.
bdbiosciences.com; and Caltag, http://www.caltag.com) for 30
min. PBMCs were washed and resuspended in RPMI 50% FBS
and kept on ice. PBMCs were sorted by ﬂow cytometry using
the BD FACSAria into CD8 T cells (CD3
þ CD8
þ CD4
  CD19
 
CD56
  CD16
 ), CD4 T cells (CD3
þ CD4
þ CD8
  CD19
  CD56
 
CD16
 ), B cells (CD19
þ CD3
  CD8
  CD4
  CD16
  CD56
 ), and
CD56dim NK cells (CD19
  CD3
  CD56dim CD16
þ) using the
gates shown in Figure S1. All antibodies used in this study
were ﬂuorescently conjugated mouse anti-human monoclonal
antibodies (BD Biosciences and Caltag). 200,000 cells were
sorted into ice-cold RPMI with 50% FBS. The sorted cells
were pelleted by centrifugation, homogenized in 1 ml of
TRIzol (Invitrogen, http://www.invitrogen.com) plus 10 lgo f
linear acrylamide, and stored at  80 8C.
Isolation and Checking of Total RNA
Total RNA was isolated from TRIzol homogenates accord-
ing to the manufacturer’s protocol and resuspended in
RNase-free water. Genomic DNA was removed using the
DNA-free kit (Ambion, http://www.ambion.com), according to
the manufacturer’s protocol. RNA quantity and quality were
checked using the Nanodrop ND1000A spectrophotometer
(Nanodrop Technologies, http://www.nanodrop.com) and the
RNA 6000 Pico LabChip assay using the Agilent 2100
Bioanalyzer (Agilent Technologies, http://www.agilent.com).
Total Lymphocyte Reference RNA for Two-Color DNA
Microarrays
PBMCs were obtained from 20 healthy donors (ten male,
ten female) ranging evenly in age from 25 to 65 years from the
Stanford Blood Center. Granulocytes and monocytes were
depleted from the PBMCs using RosetteSep depletion cock-
tails (Stemcell Technologies, http://www.stemcell.com). An
aliquot of the puriﬁed lymphocytes was taken for antibody
staining to determine purity. The cells were incubated with
ﬂuorescently conjugated monoclonal mouse anti-human
antibodies to CD3, CD56, CD16, CD8, CD4, and CD19 for
30 min, washed, analyzed by ﬂow cytometry (FACS Calibur,
BD Biosciences) and were determined to be .99% pure
lymphocytes. The remainder of the puriﬁed lymphocytes
were homogenized in 10 ml of TRIzol plus 50 lg of linear
acrylamide and stored at  80 8C. Total DNA-free RNA was
isolated. 100 lg of total RNA from each of the 20 healthy
donor total lymphocyte samples was pooled to create the
total lymphocyte reference RNA.
Amplification and Labeling of RNA
100 ng of total RNA from sorted cells or 1 lg of total
lymphocyte reference RNA was ampliﬁed using the Amino
Allyl MessageAmp II aRNA Ampliﬁcation Kit (Ambion, http://
www.ambion.com). The ampliﬁcation procedure included
incorporation of 5-(3-aminoallyl)-UTP (aaUTP) into aRNA
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hydroxysuccinimidyl ester-reactive Cy dyes. aRNA yield and
size were analyzed using the Nanodrop spectrophotometer
and the RNA 6000 Nano LabChip assay. Amino-allyl-aRNA
samples (2 lg each) were pooled in age- and gender-matched
pairs, vacuum dried to completion, and resuspended in 8 ll
of coupling buffer (Ambion). aRNA was labeled with 20,000
pmol of Cy Dye Post Labeling Reactive Dyes (Cy3 or Cy5)
(Amersham Biosciences, http://www5.amershambiosciences.
com) at room temperature for 30 min followed by addition
of hydroxylamine to 0.18 M, for 15 min at room temperature,
protected from light. Labeled aRNA was puriﬁed using the
RNeasy MinElute Cleanup kit (Qiagen, http://www.qiagen.
com). A260,A 550, and A650 were measured, and number of dye
molecules per 1,000 nucleotides was calculated using the
formula: dye molecules/1,000 nt ¼ (Adye/A260) 3 (9,101 cm
 1
M
 1 dye extinction coefﬁcient
 1) 3 1,000. The labeling
resulted in 30–60 dye molecules/1,000 nt.
Hybridization and Processing of DNA Microarrays
750 ng of Cy Dye-labeled aRNA, 750 ng of differentially
labeled total lymphocyte reference aRNA, and 50 llo f
Agilent control targets were pooled and fragmented using the
Agilent Fragmentation buffer for 30 min at 60 8C. Agilent
hybridization buffer was added, and 490 ll of target solution
was hybridized onto Agilent Human 1A Oligo Microarrays, v2
using the SureHyb (Agilent) assembly and incubated at 60 8C
at 4 rpm for 17 h. The arrays were washed and dried
according to the Agilent SSPE wash protocol, scanned using
the Agilent Microarray Scanner and the data was extracted
using the Agilent Feature Extraction Software v7.1.
Analysis of Microarray Data
The open source R software package (http://www.r-project.
org) and tools from the BioConductor project (http://www.
bioconductor.org) were used for processing and analysis of
the microarray data. The raw dataset contained 48 arrays: six
healthy and six melanoma arrays for each of the four cell
types. Two of the arrays in the data had quality problems due
to background noise and were excluded from subsequent
analysis. The manufacturer-designed control features and
features that were saturated on at least one array were
removed. For each array the variance-stabilizing normal-
ization function was applied to the mean foreground Cy5 and
Cy3 intensities, resulting in a ‘‘generalized log ratio’’ value for
each feature, followed by quantile normalization across the
arrays. The features were mapped to Entrez Gene IDs using
the Agilent Human 1A (V2) Annotation Data (hgug4110b)
package provided by BioConductor. Values from duplicate
spots for each Entrez Gene ID were summarized using the
median. The resulting data matrix contained 46 log ratio
values for 16,476 genes. The array data from each cell type
were compared separately and in various combinations in
melanoma versus healthy samples. For each combination of
two or more cell types a lower threshold of 0.01 was used for
the p-value from an F-test comparing the cell types for each
gene, such that only genes expressed at similar levels across
involved cell types were included in the comparison. A
subsequent nonspeciﬁc ﬁltering selected the top 1,000 genes
ranked by IQR across all relevant arrays. For each selected
gene a permutation-based unadjusted p-value estimate [14]
was extracted from the rawp component in the output of the
maxT function in Bioconductor’s multtest package. The p-
values were then adjusted for multiple comparisons using the
false discovery rate–controlling method [15].
Real-Time Quantitative PCR
Unampliﬁed total RNA was reverse transcribed using
Sensiscript (samples ,50ng total RNA) or Omniscript
(samples 0.05–2 lg total RNA) reverse transcriptases (Qiagen)
with 10 lM anchored Oligo(dT)23 primer and 10 lM random
nonamers in a total volume of 20 lla t3 78C for 1 h according
to the manufacturer’s protocol. 1 ll of cDNA was used as a
template in qPCR reactions in duplicate or triplicate using
SYBR Green Real Time PCR mix (Qiagen) and 300 nM
speciﬁc primers. The PCR primers (Table S1) were designed
using the Oligo 6.86 software (Molecular Biology Insights,
http://www.oligo.net) to have equivalent melting temper-
atures. At least one primer of each pair spanned an exon–
intron junction. The primers were synthesized by Elim
Biopharmaceuticals (http://www.elimbio.com). Quantitative
PCR analysis was performed using the iCycler iQ Real-Time
Detection System (Bio-Rad Laboratories, http://www.bio-rad.
com) with the following conditions: 15 min at 95 8C initial
denaturation, 40 cycles of 30 s at 95 8C, 30 s at 56 8C, 30 s at 72
8C, followed by melting analysis.
Analysis of Real-Time Quantitative PCR Data
The expression of each gene was normalized to the
housekeeping gene ubiquitin C (UBC). Two-sided Wilcoxon
rank sum tests were used to compare the healthy and
melanoma populations.
Interferon Stimulation and Detection of STAT1-pY701
PBMCs were stained with antibodies to CD8, CD4, and
CD19 for 30 min, washed and resuspended to 5310
6 cells per
test in RPMI 5% human serum and rested at 37 8C7 %C O 2
for 2 h. IFN-a, IFN-b, or IFN-c (NIAID Reference Reagent
Repository, http://www.kamtekinc.com/niaid.php; and R&D
Systems, http://www.rndsystems.com) were added to a ﬁnal
concentration of 1,000 IU/ml and cells were incubated at 37
8C and 7% CO2 for 15 min. The cells were ﬁxed by addition of
Cytoﬁx buffer (BD Biosciences) for 15 min at 37 8C and 7%
CO2, and permeabilized in Perm Buffer III (BD Biosciences)
for 30 min on ice. The cells were washed in stain buffer (13
PBS, 2% NCS, 0.09% sodium azide) and resuspended to 20 ll.
The cells were stained with 5 ll of anti-STAT1-pY701 Alexa
Fluor 647 at room temperature for 30 min, washed twice in
stain buffer, and analyzed using the FACS Aria.
Anti-CD3 Anti-CD28 Stimulation of T Cells and
Measurement of T Cell Activation
Lymphocytes were stimulated with Dynabeads CD3/CD28 T
Cell Expander beads (Invitrogen) at a bead:T cell ratio of 1:10
for measurement of CD69, CD25, and CD71, and at 1:1 for
intracellular cytokine staining, at 37 8C and 7% CO2 for 24 h.
For measurement of CD69, CD25, and CD71, cells were
stained with antibodies to CD8, CD4, CD45RA, CD27, CD19,
CD69, CD25, and CD71 for 30 min. For intracellular cytokine
staining, 5 lg/ml brefeldin A was added to cells for the ﬁnal 22
h of incubation. Cells were stained with antibodies to CD8,
CD4, and CD19, and then ﬁxed in 2% paraformaldehyde,
washed, and permeabilized in Hank’s balanced salt solution
containing 0.1% saponin and 0.01 M Hepes. Cells were
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c. Cells were washed and analyzed using the FACS Aria.
Measurement of T Cell Survival
Cell survival was measured using the Annexin V:PE
Apoptosis Detection Kit (BD Biosciences). Cells were stained
with antibodies to CD8, CD4, CD45RA, CD27, and CD19 for
30 min, and washed in Annexin V binding buffer. Annexin V-
PE and 7-aminoactinomycin D (7-AAD) were added to cells
for 15 min at room temperature. Cells were diluted in
Annexin V binding buffer and analyzed using the FACS Aria.
Analysis of Flow Cytometry Data
FCS ﬁles were analyzed using Flowjo 8.2 (Treestar, http://
www.treestar.com). The percentage of positive cells was
calculated using the Super Enhanced D-max Subtraction
method in Flowjo’s Population Comparison platform. Prob-
ability Binning (Chi[T]) in the Population Comparison
platform was used to quantitatively detect differences
between IFN-a-stimulated cells versus unstimulated cells.
One-sided Wilcoxon rank sum tests were used to make
comparisons between melanoma and healthy Phosﬂow data-
sets. A binomial test was used to evaluate the systematic trend
observed in a collection of comparisons on independent
parameters measured in the FACS-based functional assays.
Results
Target Preparation and Microarray Quality Controls
CD8 T cells, CD4 T cells, B cells, and CD56dim NK cells
were sorted to .99% purity from PBMCs from 12 patients
(six male and six female) with metastatic melanoma and age-
and gender-matched healthy controls (Figure S1). The mean
and standard deviation (in parentheses) of the ages of the
melanoma patients (n ¼ 12) and healthy donors (n ¼ 12) were
59.8 (9.6) y and 59.3 (9.2) y, respectively. The percentages of
each cell type and the naı ¨ve, effector, and memory subsets
were measured prior to sorting; there were no signiﬁcant
differences in these percentages in PBMCs from melanoma
patients versus healthy controls. Total RNA isolated from the
sorted cells was small (;200 ng); therefore, ampliﬁcation of
polyadenylated RNA was carried out to produce sufﬁcient
target material for array hybridization. Ampliﬁcation has
been shown to improve the reliability of microarray data, and
the bias introduced is minimal [16]. A total lymphocyte
reference RNA was created from the total peripheral
lymphocyte fraction from 20 healthy donors of a wide variety
of ages. This reference is much closer to the samples than the
standard reference for microarray experiments, the Universal
Human Reference RNA (Stratagene, http://www.stratagene.-
com), thus maximized our ability to resolve subtle but
statistically signiﬁcant gene expression differences between
melanoma lymphocyte subsets and healthy controls.
The reliability of the microarray data was evaluated by
quality control experiments. Dye swap and self–self hybrid-
izations showed correlations of 0.988 and 0.992, respectively,
indicating very high consistency between the two labeling
colors (Figure S2A and S2B). Replicate arrays within and
between batches were included to measure the reproduci-
bility of the hybridizations. The array-to-array correlation for
pairs of replicate arrays within a batch was 0.987 (Figure S2C),
and the batch-to-batch correlation ranged from 0.971 to
0.992. Prior to labeling and hybridization, aRNA samples
were pooled into age- and gender-matched pairs, i.e., the 12
melanoma patient samples were hybridized as six pairs of
samples, and each pair was gender-matched and closely age-
matched. This pooling strategy has been shown to reduce the
variation and noise in microarray data and to increase
statistical power [17,18]. We chose this strategy for our
experiments to further improve the sensitivity to detect
subtle differences in gene expression between the patients
and healthy donors.
Gene Expression Changes in T and B, but Not NK Cells
from Melanoma Patients versus Healthy Controls
The open-source R software package (http://www.r-project.
org) and tools from BioConductor (http://www.bioconductor.
org) were used for processing the microarray data as
described in Methods. For CD8 T cells, CD4 T cells, and B
cells, a similar set of genes with common regulation by IFNs
showed reduced expression in patients with melanoma versus
healthy controls. As such, data from these three cell types
were combined to increase the statistical power of the
analysis. Of the top 25 genes ranked by adjusted p-value, 17
are regulated by IFNs (Table 1). The products of IFN-
stimulated genes (ISGs) are responsible for the antiviral,
antiproliferative, and immunomodulatory effects of IFNs.
Of 1,000 genes that were used as input into the multiple
testing procedure, 25 were ISGs; 17 of these 25 genes have an
adjusted p-value , 0.05, in contrast to eight of 975 non-IFN-
stimulated genes that have an adjusted p-value , 0.05. A
hypergeometric test was used to evaluate this over-represen-
tation of ISGs in the group of genes discriminating melanoma
lymphocytes from healthy controls. The resulting p-value was
less than 10
 27, strongly indicating the reduced expression of
ISGs as a highly signiﬁcant difference between lymphocytes
from patients with melanoma and those from healthy
controls. An extensive study of how the differential expres-
sions in T cells and B cells are related was done through a
gene interaction program (Nacu et al., unpublished technical
report, 2006, Department of Statistics, Stanford University).
Hierarchical clustering of the microarray data was per-
formed using the heatmap function in R for the top ten ISGs
ranked by adjusted p-value for CD8 T cells, CD4 T cells, and B
cells. This clustering separated the samples into two main
groups, one of patients with melanoma with low expression of
this set of ISGs and another of mainly healthy donors with
higher expression (Figures 1A and S3A–S3C). Three arrays
from two pairs of patients with melanoma fell into an
intermediary subset containing healthy samples with expres-
sion intermediate between the low ISG-expressing melanoma
and the high ISG-expressing healthy samples (Figure 1A).
Interestingly, no signiﬁcant alterations in gene expression
were detected between NK cells from melanoma patients
versus healthy controls. The set of ISGs did not discriminate
between the NK cells from melanoma and healthy samples
(Figure 1B). Moreover, the top ranked genes for NK cells were
also not able to discriminate between the two groups (Figure
S3D), further conﬁrming that the gene expression proﬁles of
NK cells are not altered in melanoma patients.
Validation of Microarray Data by Quantitative PCR
The altered expression of ISGs in T and B cells from patients
with melanoma observed in the microarray experiments was
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genes using unampliﬁed RNA reserved from the original,
sorted samples prior to microarray analysis. The qPCR analysis
showed reduced expression of ISGs in CD8 T cells, CD4 T cells,
and B cells from patients with melanoma versus healthy
controls, validating the microarray data (p , 0.05 for each
gene, Table 2). The mean fold change in expression of these
genes between the melanoma and healthy samples ranged from
1.5443 for HERC5 to 3.0053 for IFI44 (Table 2). HERC5 gene
regulation is not well understood, but expression of HERC5 is
induced in response to IFN-a (unpublished data). Two other
non-IFN-regulated genes were also found to be signiﬁcantly
altered in expression in lymphocytes from patients with
melanoma compared to healthy controls: LAMP3 expression
was reduced and FREQ expression was increased (Table 1).
These expression changes were also validated by qPCR, with p-
values of 0.006 and 0.054 for LAMP3 and FREQ, respectively. A
set of the top-ranking genes for NK cells from patients with
melanoma and ISGs were chosen for analysis by qPCR. The
expression of these two sets of genes in NK cells was not
signiﬁcantly different between patients with melanoma and
healthy controls (Table S2).
STAT1-Tyrosine Phosphorylation in Lymphocytes
The reduced expression of STAT1 and ISGs in T and B cells
from patients with melanoma indicates a perturbation in IFN
signaling in the immune system of these patients. To test this
hypothesis, the functional response of lymphocytes to IFN
stimulation was assessed by measurement of STAT1 phos-
phorylation, an essential event in signal transduction by IFNs.
PBMCs from nine patients with melanoma and nine healthy
controls were stimulated with 1,000 IU/ml IFN-a, IFN-b,o r
IFN-c (or left unstimulated), and phosphorylation of STAT1
at tyrosine 701 was measured using Phosﬂow (BD Bioscien-
ces). The Phosﬂow method has greater sensitivity and is more
quantitative than other methods, and it allows simultaneous
analysis of multiple populations in small clinical samples. The
concentration of 1,000 IU/ml was chosen for two reasons: (i)
this concentration produced maximal induction of STAT1-
pY701 for detection by the assay in titration experiments, and
(ii) this is approximately the serum concentration of IFN-a2b
reached in humans after intravenous infusion of IFN-a2b in
the high-dose treatment regimen of 2 3 10
7 IU/m
2 (unpub-
lished data). The median percentage of phosphorylated
STAT1-positive lymphocytes induced by IFN-a stimulation
was signiﬁcantly reduced (D ¼ 16.28%; 95% CI, 0.98 to 33.35,
Figure 2A) in the patients with melanoma (n¼9) compared to
the healthy controls (n ¼ 9). Within the lymphocyte
population, a reduction was observed in CD8 (D ¼ 10.18%)
and CD4 T cell (D ¼ 8.71%) subsets, but not in B cells (D ¼
0.33%) (Figure 2B–2D). A similar pattern of reduction in the
median percentage of STAT1-pY701-positive lymphocytes
was observed with IFN-b stimulation (Figure 2E–2H). In
response to IFN-c stimulation, no signiﬁcant difference was
observed in phosphorylation of STAT1 in melanoma patient
samples compared to controls (Figure 2I–2L). These results
also indicate that there are two groups of patients: high (3/9)
and low (6/9) responders to IFN-a.
Table 1. Genes Showing Differential Expression between Patients with Melanoma and Healthy Controls in Combined Microarray Data
from CD8 T Cells, CD4 T Cells, and B Cells
Entrez
Gene ID
Entrez Gene
Symbol
Entrez Gene Name Adjusted
p-Value
" or # in
Melanoma
3437 IFIT3
a Interferon-induced protein with tetratricopeptide repeats 3 0.00125 #
91543 RSAD2
a Radical S-adenosyl methionine domain containing 2 0.00125 #
129607 LOC129607 Hypothetical protein LOC129607 0.00125 #
10964 IFI44L
a Interferon-induced protein 44-like 0.00125 #
3434 IFIT1
a Interferon-induced protein with tetratricopeptide repeats 1 0.00125 #
3433 IFIT2
a Interferon-induced protein with tetratricopeptide repeats 2 0.00125 #
4940 OAS3
a 29,59-Oligoadenylate synthetase 3, 100 kDa 0.00125 #
23413 FREQ Frequenin homolog (Drosophila) 0.00125 "
4938 OAS1
a 29,59-Oligoadenylate synthetase 1, 40/46 kDa 0.00200 #
6772 STAT1
a Signal transducer and activator of transcription 1, 91 kDa 0.00200 #
10561 IFI44
a Interferon-induced protein 44 0.00250 #
9636 ISG15
a ISG15 ubiquitin-like modifier 0.00250 #
219285 SAMD9L Sterile alpha motif domain containing 9-like 0.00385 #
83666 PARP9 Poly (ADP-ribose) polymerase family, member 9 0.00400 #
6373 CXCL11
a Chemokine (C-X-C motif) ligand 11 0.00400 #
2633 GBP1
a Guanylate binding protein 1, interferon-inducible, 67 kDa 0.00688 #
3627 CXCL10
a Chemokine (C-X-C motif) ligand 10 0.02278 #
4600 MX2
a Myxovirus (influenza virus) resistance 2 (mouse) 0.02278 #
5610 EIF2AK2
a Eukaryotic translation initiation factor 2-alpha kinase 2, interferon-inducible 0.02526 #
27074 LAMP3 Lysosomal-associated membrane protein 3 0.02950 #
11274 USP18
a Ubiquitin specific peptidase 18 0.03143 #
54809 SAMD9 Sterile alpha motif domain containing 9 0.03545 #
5359 PLSCR1 Phospholipid scramblase 1 0.03565 #
54739 BIRC4BP XIAP associated factor-1 0.04333 #
3429 IFI27
a Interferon, alpha-inducible protein 27 0.04440 #
Expression levels were measured by DNA microarray analysis, and genes are ranked in order of significance according to adjusted p-value.
aInterferon-stimulated gene.
doi:10.1371/journal.pmed.0040176.t001
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was used to compare the distributions of STAT1-pY701-
stained cells in IFN-a-stimulated lymphocytes to correspond-
ing unstimulated controls. Melanoma samples had a lower
mean Chi
2(T) value (3,830 6 978.5) than the healthy (6,398 6
1,453) for STAT1-pY701, further indicating that the induc-
tion of STAT1-pY701 by IFN-a stimulation was lower in
melanoma compared to the healthy samples.
Two comparisons were made of the fold change in mean
ﬂuorescence intensity of STAT1-pY701 staining in stimulated
versus unstimulated cells: the total fold change in stimulated
versus unstimulated cells, and the fold change in STAT1-
pY701-positive cells versus unstimulated cells. The total fold
change in STAT1-pY701 staining in IFN-a and IFN-b, but not
IFN-c, in stimulated versus unstimulated cells was systemati-
cally lower in CD8 (healthy [H], 2.763; melanoma [M], 1.843)
and CD4 T cell (H, 3.323; M, 2.93) subsets and in the
lymphocyte population as a whole (H, 2.843; M, 1.813) (Figure
3A–3C), supporting the results demonstrating reduced
response of lymphocytes to type I IFNs. The fold change in
mean ﬂuorescence intensity of STAT1-pY701-positive cells
versus unstimulated cells was not signiﬁcantly different
between healthy (3.953) and melanoma (3.953) lymphocytes
(Figure 3D). These results indicate that those cells able to
respond to IFN in the melanoma samples do so to a level
similar to healthy lymphocytes. In the melanoma group, the
fold change in STAT1-pY701-positive cells was signiﬁcantly
correlated with the percentage of STAT1-pY701-positive cells
in response to IFN-a (r¼0.8841, p¼0.0016). In contrast, there
was a lower and non-signiﬁcant correlation (r ¼ 0.5785, p ¼
0.1027) in the healthy group. This result indicates that the
lower percentage of cells responding to IFN-a in the
melanoma patient group is associated with a lower magnitude
of response to IFN-a in these cell populations. Overall, these
functional assays indicate a defect speciﬁcally in type I IFN
signaling in T cells from patients with melanoma.
Expression of ISGs in Lymphocytes upon IFN Stimulation
The reduced phosphorylation of STAT1 may impair the
ability of cells to induce downstream expression of ISGs. To
test this hypothesis, lymphocytes from patients with melano-
ma and healthy controls were stimulated with 1,000 IU/ml
IFN-a or unstimulated for 14 h, after which the cells were
homogenized in TRIzol for RNA isolation, followed by cDNA
synthesis. Real-time qPCR was performed for four ISGs
shown to be signiﬁcantly down-regulated in the microarray
data: STAT1, IFIT1, IFI44, and MX2. The expression level of
these genes in IFN-~ a-stimulated cells was lower in the
melanoma group compared to the healthy group, although
the difference in expression was not statistically signiﬁcant
for three of the four genes (Figure 4A). This indicates that
prolonged exposure to high-dose IFN could partially over-
come the defect in IFN signaling in lymphocytes from
patients with melanoma. The fold change in expression of
STAT1, IFI44, and MX2 in stimulated versus unstimulated
cells (calculated using the Pfafﬂ method [20]) was higher in
the melanoma patient samples (Figure 4B). Despite the higher
median fold change in these patients, the level of expression
of these ISGs did not reach that observed in the healthy
samples (Figure 4A). The patients with the lowest basal
expression of these genes had the lowest fold change in
response to IFN-a; e.g., melanoma patients #2 and #11 are two
of the lowest-ranking in basal expression of STAT1, IFIT1,
IFI44, and MX2 and showed the lowest fold changes for these
genes, and the lowest response to IFN-a in the Phosﬂow assay
out of the group of patients with melanoma, further
indicating that some of these patients are IFN-low-respond-
ers. Patients with higher basal expression of these genes
Figure 1. Hierarchical Clustering of the Microarray Data Using ISGs
Hierarchical clustering of the microarray data was performed using the
ten ISGs with lowest adjusted p-values in combined data from B cells,
CD8 T cells, and CD4 T cells (A) and CD56dim NK cells (B) from patients
with melanoma versus healthy controls. White indicates highest
expression, red indicates lowest, and yellow/orange indicates interme-
diary expression in melanoma versus healthy control.
doi:10.1371/journal.pmed.0040176.g001
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expression of these ISGs, indicating that other patients are
IFN responsive. The difference in patient responses may
explain why some patients with melanoma respond to high-
dose IFN-a2b therapy while others do not.
T Cell Expression of Activation Markers and Survival
Following Stimulation
Type I IFNs have both direct and indirect roles in
supporting full activation and survival of T cells [21]. The
impaired response to type I IFN may negatively impact the
function of T cells in melanoma. To determine the functional
status of T cells from the patients with melanoma, lympho-
cytes were stimulated with beads coated with anti-CD3 and
anti-CD28 antibodies. T cell responses were assayed by
measurement of surface markers of activation and cytokine
production. At 6 h poststimulation, expression of CD69 was
lower in the IFN-low-response patients (n ¼ 5) compared to
the healthy controls (n¼10) in each of the naı ¨ve, effector and
memory, and CD27  CD45RA  subsets of CD8 and CD4 T
cells (Figures 5A and S4). Correlations were made to
determine whether the low response to IFN in the Phosﬂow
assay was associated with the reduced expression of CD69 in
lymphocytes from patients with melanoma following CD3/
CD28 stimulation. The expression of CD69 was signiﬁcantly
correlated with the percentage of STAT1-pY701-positive
lymphocytes following IFN-a stimulation (r ¼ 0.9829, p ¼
0.0027, Figure S5) in the IFN-low-response patients. In
contrast, the melanoma group as a whole showed lower
correlation between the percentage of STAT1-pY701-positive
lymphocytes following IFN-a stimulation and the expression
of CD69 (r ¼ 0.6786, p ¼ 0.0643), while in the healthy group
there was no correlation at all in this respect (r¼ 0.0044, p¼
0.9909, Figure S5). These correlation results indicate an
association between low response to IFN and reduced
expression of CD69 by lymphocytes from IFN-low-response
patients and a more pronounced functional defect in these
patients compared to the melanoma group as a whole.
At 24 h poststimulation, expression of three early and late
surface markers of activation—CD69, CD25, and CD71—was
systematically reduced in the IFN-low-response patients’ (n ¼
3) compared to the healthy controls’ (n¼13) CD8 and CD4 T
cells (Figures 5B and S6–S8). The expression of TH1-type
cytokines IL-2, TNF-a, and IFN-c was also reduced in T cells
from these patients (n ¼ 5) versus healthy controls (n ¼ 13) in
response to stimulation (Figures 5C and S9). There was a
higher correlation between the percentage of stimulated CD8
or CD4 T cells expressing IL-2 with the percentage of STAT1-
pY701-positive CD8 or CD4 T cells following IFN-a stim-
ulation in the IFN-low-response group of patients (CD8, r ¼
0.9065; CD4, r ¼ 0.4670, respectively) compared to the
melanoma group as a whole (CD8, r ¼ 0.1086; CD4, r ¼
0.01028) or the healthy donors (CD8, r ¼  0.35580; CD4, r ¼
0.1242), indicating that there is a close link between impaired
response to IFN and low expression of IL-2 in the IFN-low-
response group of patients with melanoma, and that this
group of patients has a more pronounced functional defect
than the melanoma group as a whole. The survival of T cells
following stimulation was also measured. The survival
percentage (Annexin V-negative 7-AAD-negative cells) was
reduced in CD8 and CD4 T cells from the subset of IFN-low-
response patients 4 d after stimulation (Figures 5D and S9).
In each of these functional assays there was a systematic
trend of reduced responses to activating stimuli in lympho-
cytes from patients with melanoma versus healthy controls.
Ten of the comparisons presented in Figure 5 are essentially
independent; i.e., the expression of CD69 in each of the four
T cells subsets at 6 h; the expression of CD69, CD25, and
CD71 in these subsets at 24 h; cytokine expression in T cells;
and survival in T cells. The probability of observing this trend
across these ten comparisons by chance is very small (p ,
0.001). These impaired activation responses and reduced
survival of CD8 and CD4 T cells from patients with melanoma
Table 2. Real-Time Quantitative PCR Analysis of Genes Differentially Expressed in CD8 T Cells, CD4 T Cells, and B Cells from Patients
with Melanoma versus Healthy Controls
Entrez
Gene Symbol
p-Value Estimated Log2 Fold
Differences, Log2(H/M)
(95% CI)
Estimated Fold
Differences (H/M)
Sample Sizes (B, CD8, CD4)
HM
EIF2AK2 0.0020 0.998 (0.349 to 1.833) 1.997 5,5,5 5,5,5
IFI44 0.0023 1.587 (0.620 to 2.632) 3.005 5,5,5 5,5,4
IFIT3 0.0023 1.294 (0.410 to 2.128) 2.452 6,8,8 6,7,8
IFIT1 0.0048 1.345 (0.447 to 2.824) 2.539 5,8,5 5,7,5
IFIT2 0.0146 0.995 (0.171 to 2.147) 1.993 7,8,8 6,8,8
STAT1 0.0178 1.344 (0.254 to 2.376) 2.539 6,12,8 6,12,8
OAS1 0.0245 0.893 (0.151 to 1.740) 1.857 9,6,5 7,8,5
MX1 0.0253 1.001 (0.1 to 1.949) 2.002 5,6,5 5,8,4
MX2 0.0293 0.895 (0.052 to 1.791) 1.859 8,5,5 6,7,4
IFI44L 0.0305 1.039 (0.105 to 2.188) 2.055 5,6,9 5,6,7
RSAD2 0.0380 0.994 (0.002 to 2.188) 1.991 5,7,8 5,5,7
HERC5 0.0563 0.626 ( 0.028 to 1.377) 1.544 7,9,7 7,9,7
QPCR was used to measure expression of genes shown by microarray analysis to be differentially expressed in melanoma versus healthy samples. The Wilcoxon rank sum test (two-sided)
was used to calculate the p-values. The estimated log2 fold differences (log2[H/M]) between healthy controls and patients with melanoma with 95% CIs and estimated fold differences (H/
M) are shown. Data from B cells, CD8 T cells, and CD4 T cells were pooled for analysis; the number of samples of each cell type is indicated.
doi:10.1371/journal.pmed.0040176.t002
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response patients.
Discussion
Dysfunction or nonresponsiveness of the immune system
may be an early event in tumor progression, while global
immune suppression develops in most patients with meta-
static disease [1,2]. The molecular mechanisms underlying
immune dysfunction in cancer remain unclear. In this study,
we studied lymphocytes from patients with metastatic
melanoma at the level of gene expression using DNA
microarrays to identify immune signatures that are associated
with the cancer state. To resolve gene expression changes in
speciﬁc lymphocyte subsets, we analyzed pure cell popula-
tions, stringently sorted by ﬂow cytometry to allow precise
analysis of each cell type. Our study included all the
peripheral blood lymphocyte populations that are potentially
involved in antitumor responses and may be negatively
impacted by tumors, speciﬁcally CD8 T cells, CD4 T cells, B
cells, and CD56dim NK cells. Inhibition of these key immune
cell subsets in cancer may aid tumor progression and
confound immunotherapeutic approaches.
In CD8 T cells, CD4 T cells, and B cells, our results showed
that a group of related genes all induced by IFN, e.g., STAT1,
IFIT1, and IFI44, were signiﬁcantly reduced in expression in
patients with melanoma versus healthy controls. These gene
expression changes were further validated by qPCR. No
statistically signiﬁcant differences in gene expression were
detected in NK cells from patients with melanoma versus
healthy controls. The detection of differentially expressed
genes that belong to a common pathway validates our
approach of using DNA microarrays as a powerful tool to
identify pathways and mechanisms of immune dysfunction in
cancer. The ﬁnding that a group of ISGs is down-regulated in
Figure 2. Percentage of STAT1-pY701-Positive Cells in Lymphocytes from Patients with Melanoma and Healthy Controls in Response to IFN Stimulation
PBMCs from patients with melanoma and healthy controls were stimulated with 1,000 IU/ml IFN-a, IFN-b, or IFN-c. The percentage of STAT1-pY701-
positive cells was measured by Phosflow. p-Values were calculated using the Wilcoxon rank sum test (one-sided). Medians are indicated by the bar in
each scatter column. H, healthy; M, melanoma.
(A–D) IFN-a-stimulated PBMCs. Lymphocytes (A); CD8 T cells (B); CD4 T cells (C); B cells (D).
(E–H) IFN-b-stimulated PBMCs. Lymphocytes (E); CD8 T cells (F); (G) CD4 T cells (G); B cells (H).
(I–L) IFN-c-stimulated PBMCs. Lymphocytes (I); CD8 T cells (J); CD4 T cells (K); B cells (L).
doi:10.1371/journal.pmed.0040176.g002
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pathways as a dominant mechanism in the dysfunction of
immune cells in patients with metastatic melanoma.
IFN-stimulated gene expression is regulated by the JAK-
STAT (Janus kinase–signal transduction and activator of
transcription) signaling pathway. Binding of type I IFNs, such
as IFN-a and IFN-b, to their speciﬁc receptor leads to
phosphorylation of JAK1 and Tyk2, which in turn phosphor-
ylate STAT2 and STAT1. Phosphorylated STAT1–STAT2
heterodimers associate with IRF9 to form interferon-stimu-
lated gene factor 3 (ISGF3), which binds to interferon-
stimulated response elements (ISREs) in the promoters of
ISGs, including those observed to be down-regulated in
patients with melanoma in our study. Type II IFN (IFN-c)
causes activation and phosphorylation of JAK2 and JAK1,
leading to phosphorylation of STAT1. Phosphorylated
STAT1 homodimers bind to GAS (c-activated sequence)
elements of ISG promoters [22]. We assessed phosphorylation
of STAT1 at tyrosine 701 in response to IFN stimulation,
since this is a critical event in transduction of signal from
both types of IFN receptors to the nucleus to drive expression
of ISGs. Using the Phosﬂow method we demonstrated that the
percentage of lymphocytes from patients with melanoma,
particularly T cells, that phosphorylated STAT1 on tyrosine
701, and the mean fold change in intensity of STAT1-pY701
staining in response to IFN-a and IFN-b, were reduced
compared to the healthy controls. The defect in STAT1
phosphorylation suggests a mechanism for the low expression
of ISGs in T cells from patients with melanoma, since
phosphorylation of STAT1 is critical for assembly of ISGF3
for the activation of ISGs. Other studies have documented
mutations in components of the JAK-STAT pathway in tumor
cells; however, to our knowledge this is the ﬁrst study to
report defects in IFN signaling in immune cells of patients
with melanoma.
This defect in lymphocytes from patients with melanoma
appears to be speciﬁc to type I IFN signaling, since no
perturbation of STAT1 phosphorylation was observed in IFN-
c-stimulated samples from patients with melanoma. It is
therefore possible that the defect in STAT1 phosphorylation
is linked to the function of JAK-STAT components that are
unique to the signaling complex induced by type I IFNs, e.g.,
Tyk2. However, STAT1 phosphorylation at tyrosine 701 is low
following IFN-c stimulation, which may prevent detection of
small differences between patient and control samples by
Phosﬂow. Furthermore, there is cross talk between the two
classical JAK-STAT signaling pathways induced by type I and
II IFNs, and between nonclassical pathways such as the CRKL,
p38, and PI3K cascades (reviewed in [23]). Therefore, the
reduced phosphorylation of STAT1 in response to IFN-a may
also impact IFN-c signaling in lymphocytes from patients
with melanoma in vivo even though such defects are less
readily detectable in vitro.
IFNs represent the ﬁrst line of defense against viral
infections and are also involved in immune surveillance
against tumors. In the early phases of an immune response,
Figure 3. Fold Change in Mean Fluorescence Intensity of STAT1-pY701-Alexa Fluor 647 Staining in Lymphocytes from Patients with Melanoma and
Healthy Controls in Response to IFN Stimulation
The mean fluorescence intensity (MFI) of STAT1-pY701-Alexa Fluor 647 staining was measured by Phosflow in IFN-stimulated (1,000 IU/ml) and
unstimulated cells. Total fold change ¼ MFI stimulated cells/MFI-unstimulated cells; positive cell fold change ¼ MFI STAT1-pY701-positive cells/MFI-
unstimulated cells. p-Values were calculated using the Wilcoxon rank sum test (one-sided). Medians are indicated by the bar in each scatter column.
Healthy (&; n ¼ 9); melanoma (&; n ¼ 9).
(A) IFN-a-stimulated cells.
(B) IFN-b-stimulated cells.
(C) IFN-c-stimulated cells.
(D) Positive cell fold change in lymphocytes.
doi:10.1371/journal.pmed.0040176.g003
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(antigen) and second (co-stimulation) signals for full activa-
tion and memory development rather than tolerance [21].
IFNs support activation and clonal expansion via antiapop-
totic and proproliferative effects on both T and B lympho-
cytes [24–28]. We investigated the functional signiﬁcance of
the observed impaired responses to IFN by assaying the
activation and survival of lymphocytes from patients with
melanoma. These experiments focused on the subgroup of
patients in which low responses to type-I IFNs were observed.
This set of IFN-low-response patients showed reduced T cell
activation responses and lower survival following stimulation
with anti-CD3 and anti-CD28 antibodies. These results
demonstrate that lymphocytes from these patients have
pronounced functional defects, likely arising from their
impaired response to IFN, resulting in lack of the third
signal required to initiate the differentiation program for
survival and development of effector function and memory.
Poor survival and/or increased apoptosis and impaired
responses of lymphocytes to stimulation are critical aspects
of immune dysfunction in the cancer state. Increased
apoptosis has been associated with FasL and other tumor
necrosis factor (TNF) family ligands expressed by cancer cells
and on tumor-derived microvesicles [4,29–31] and also with
tumor-derived gangliosides [32,33]. Reduced activation and
clonal expansion of lymphocytes have been linked to
disruption of the TCR signaling cascade by decreased
expression of CD3 f chain and other signaling components
[34–37]. Impaired responses to type I IFNs in cancer patients,
as shown in our study, represent a novel mechanism by which
lymphocytes may be driven into apoptosis and have poor
functional responses to activating stimuli in the cancer state.
Impaired responses to IFNs at each phase of adaptive
immune responses likely contribute to the observed immune
low responsiveness and lack of antitumor immunity observed
in cancer and may also hinder therapeutic approaches that
aim to stimulate antitumor immune responses. The defect in
IFN signaling may be directly tumor-induced, or an effect of
the general cancer state. Alternatively, the defect may be
involved in the development of the melanoma. Our ﬁndings
may go beyond tumor-induced immune dysfunction; defects
in IFN signaling have been documented in other chronic
diseases in which immune dysfunction has been described,
e.g., chronic hepatitis C infection and multiple sclerosis
[38,39].
Phosphorylation of STAT1 is an early proximal event in
Figure 4. Expression of ISGs in Lymphocytes from Patients with Melanoma and Healthy Donors Stimulated with IFN-a
Lymphocytes from patients with melanoma and healthy controls were stimulated with 1,000 IU/ml for 14 h. The expression of STAT1, IFIT1, IFI44, and
MX2 were measured by qPCR. Data are shown on a log2 scale. Medians are indicated by the bar in each scatter column. p-Values are from one-sided
Wilcoxon rank sum test. H, healthy; M, melanoma.
(A) Gene expression in IFN-a-stimulated cells, sample sizes were n ¼ 13 (H) and n ¼ 12 (M) for each gene.
(B) Fold change in gene expression in IFN-a–stimulated cells versus unstimulated control cells. STAT1: n¼13 (H), n¼11 (M); IFIT1: n¼12 (H), n¼12 (M);
IFI44: n ¼ 13 (H), n ¼ 11 (M); MX2: n ¼ 12 (H), n ¼ 12 (M).
doi:10.1371/journal.pmed.0040176.g004
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phorylation may be caused by alterations in the function of a
limited number of other components, including JAK1, Tyk2,
and the regulators of JAK-STAT signaling. The mRNA levels
of the IFN receptor subunits STAT2, JAK1, JAK2, and Tyk2
were not signiﬁcantly different in lymphocytes from patients
with melanoma in our microarray data; however, altered
function of these molecules may be involved in the impaired
phosphorylation of STAT1 in response to IFNs. Regulation of
IFN signaling occurs at several levels, including expression
and turnover of IFN receptor components, and activation
and turnover of intracellular signaling molecules. Three
classes of negative regulators have been described to
attenuate IFN signaling through their actions on STAT1.
These include protein tyrosine phosphatases, such as Src
homology 2 (SH2)-containing phosphatase-1 and  2 (SHP-1
and  2) and CD45, protein inhibitors of activated STATS
(PIAS) that are constitutively present and function as acute,
early regulators of cytokine signaling [40], and the suppres-
sors of cytokine signaling (SOCS) that are rapidly induced by
cytokines and form a classical negative feedback loop to
regulate JAK-STAT signaling [41]. Tumor or tumor-associ-
ated cells actively and directly inhibit immune responses via
secretion of immunosuppressive cytokines such as interleukin
(IL)-10 [42] and transforming growth factor (TGF)-b1 [43,44],
and by skewing CD4 T cell responses to TH2 rather than TH1
[45,46]. Such cytokines produced in the cancer state may be
involved in the mechanism by which IFN signaling is
inhibited in lymphocytes in patients with melanoma through
their ability to induce expression of the negative regulators of
IFN signaling [47–51]. In addition to tumor production of
immunosuppressive cytokines, regulatory T cells—which are
expanded in cancer patients [52,53]—produce cytokines such
as IL-10 and TGF-b1 and may contribute to the inhibition of
IFN signaling in lymphocytes in the cancer state.
The low response to IFN-a was partially corrected in
lymphocytes from patients with melanoma by prolonged
exposure of lymphocytes to high concentrations of IFN-a in
vitro, demonstrating that the defect may be reversed by IFN
therapy in some patients. There was variation and overlap
Figure 5. Activation and Survival of CD8 and CD4 T Cells in Response to Activating Stimulus
Lymphocytes from patients with IFN-nonresponsive melanoma and healthy donors were stimulated with beads coated with anti-CD3 and anti-CD28
antibodies.
(A) Percentage of CD8 and CD4 T cells expressing CD69 at 6 h following stimulation (mean and standard error).
(B) Percentage of CD8 and CD4 T cells expressing CD69, CD25, and CD71 (data combined) at 24 h following stimulation (mean and standard error).
(C) Percentage of CD8 and CD4 T cells expressing IL-2, TNF-a, and IFN-c (data combined) at 24 h following stimulation.
(D) Percentage of surviving (Annexin V-negative 7-AAD-negative) cells at 4 d following stimulation. Means are indicated by the bar in scatter columns.
doi:10.1371/journal.pmed.0040176.g005
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and the qPCR data measuring induction of ISGs. This
variation indicates that the defect is not signiﬁcant in all
patients with melanoma, but in a subset of patients that
speciﬁcally rank lowest in their in vitro response to IFN. The
reduced response of lymphocytes from some patients with
melanoma to high-dose IFN indicates a severe impairment in
IFN signaling in a subset of patients. The efﬁcacy of IFN
therapy for cancer is thought to be dependent both on direct
antiproliferative effects on the tumor and on indirect
immunomodulatory effects [54–56]. It is clear from the
clinical trials that while some patients respond well to IFN
therapy, others are low responders in whom IFN-a has no
clinical beneﬁt. A defect in type I IFN signaling in
lymphocytes as demonstrated in our study may provide a
mechanism for the beneﬁcial effect of IFN in melanoma, and
for the resistance to IFN observed in some patients. One of
the main limitations of IFN therapy is severe toxicity. Our
results may aid in selecting patients likely to have a positive
lymphocyte response to IFN and a good clinical outcome, and
could avoid unnecessary toxicity in patients with impaired
IFN signaling who may be less likely to beneﬁt from high dose
IFN therapy.
In summary, we have identiﬁed defects in IFN signaling as a
dominant mechanism of immune dysfunction in the cancer
state. Our study utilized multiple novel technologies to
demonstrate a defect in type I IFN signaling in T cells and
B cells, but not in NK cells from patients with metastatic
melanoma, and that such defects negatively impact the
function of these cells. Such lymphocytes also displayed
reduced activation and survival in response to in vitro
stimulation. The reduced responses to IFNs could be involved
in the susceptibility of lymphocytes to spontaneous apoptosis
in the cancer state and to general immune nonresponsive-
ness, both of which are critical aspects of tumor-induced
immune dysfunction. Our data also show that the impairment
can be partially overcome by prolonged high-dose IFN-a
treatment, suggesting a potential mechanism for the efﬁcacy
of IFN-a used in the therapy of melanoma. Deregulation of
IFN signaling has been described as involved in tumorigenesis
[57]; however, to our knowledge this study is the ﬁrst to ﬁnd a
defect in IFN signaling in immune cells in the cancer state.
Our ﬁndings represent an important insight into immune
dysfunction in cancer, and may lead to novel strategies to
correct this dysfunction in cancer patients and to improve
immunotherapeutic strategies for cancer.
Supporting Information
Figure S1. FACS Plots Indicating Sorting Gates for Lymphocyte
Subsets
Data on PBMCs were acquired and a gate was set on the lymphocytes
on a FSC-A versus SSC-A plot (not shown). Gates were set on the
CD19
þCD3
 cells to sort B cells, on CD3
þCD56
 CD16
 CD8
þcells to
sort CD8 T cells, on CD3
þCD56
 CD16
 CD4
þcells to sort CD4 T cells
and on CD3
  CD19
  CD16
þ CD56dim cells to sort CD56dim NK cells
as indicated in the plots.
Found at doi:10.1371/journal.pmed.0040176.sg001 (1.7 MB TIF).
Figure S2. Microarray Quality Control Plots
The vsn function was applied to the raw intensity microarray data
after removal of 99 saturated features and one outlier feature.
(A) Microarray data from a dyeswap experiment. Microarrays were
hybridized with Cy3-CD8 aRNA and Cy5-TLR (total lymphocyte
reference) aRNA, or Cy5-CD8 aRNA and Cy3-TLR aRNA. Cy3-CD8
data from one array and Cy5-CD8 data from the second half of the
dye swap experiment were combined, and Cy3 signal was plotted
against Cy5 signal.
(B) Microarray data from a self-self experiment. Microarrays were
hybridized with Cy3-CD8 targets and Cy5-CD8 targets from the same
aRNA sample. Cy3 signal was plotted against Cy5 signal.
(C) Microarray data from replicate samples. Two microarrays were
hybridized with Cy3-CD8 and Cy5-TLR targets; Cy3 signal from each
array is plotted.
Found at doi:10.1371/journal.pmed.0040176.sg002 (1.9 MB TIF).
Figure S3. Hierarchical Clustering of Microarray Data
This was performed using the 10 ISGs with lowest adjusted p-values in
B cells (A), CD8 T cells (B), and CD4 T cells (C) from patients with
melanoma versus healthy controls. Hierarchical clustering of the
microarray data was also performed using the top ranking genes
discriminating CD56dim NK cells from patients with melanoma
versus controls (D). White indicates highest expression, red indicates
lowest gene, and yellow/orange indicates intermediary expression in
melanoma versus healthy.
Found at doi:10.1371/journal.pmed.0040176.sg003 (8.7 MB TIF).
Figure S4. Scatter Plots to Show Percentage of CD8 and CD4 T Cells
Expressing CD69 Six Hours after Stimulation
Lymphocytes from IFN-low-response patients and healthy donors
were stimulated with beads coated with anti-CD3 and anti-CD28
antibodies. Expression of CD69 was measured by ﬂow cytometry 6 h
after stimulation in CD8 and CD4 T cells. Healthy (*); melanoma ( ).
Found at doi:10.1371/journal.pmed.0040176.sg004 4.4 MB TIF).
Figure S5. Correlation of Phosﬂow data with expression of CD69 in
stimulated lymphocytes
Lymphocytes from patients with melanoma and healthy controls were
stimulated with 1,000 IU/ml IFN-a for 15 min and the percentage of
pSTAT1 pY701-positive cells was determined by Phosﬂow (x-axis).
Lymphocytes from the same patients and healthy controls were
stimulated with beads coated with anti-CD3 and anti-CD28 anti-
bodies and the percentage of CD69-positive cells was measured by
ﬂow cytometry at 6 h (y-axis). (A) Healthy lymphocytes, r¼ 0.0044, p
¼ 0.9909; (B) melanoma lymphocytes, r ¼ 0.6786, p ¼ 0.0643; (C) IFN-
low-responder melanoma lymphocytes, r ¼ 0.9829, p ¼ 0.0027.
Correlation coefﬁcients and p-values were calculated using the
Pearson correlation function in GraphPad Prism v3.02.
Found at doi:10.1371/journal.pmed.0040176.sg005 (125 KB TIF).
Figure S6. Scatter Plots to Show Percentage of CD8 and CD4 T Cells
Expressing CD69 24 Hours after Stimulation
Lymphocytes from IFN-low-response patients with melanoma and
healthy donors were stimulated with beads coated with anti-CD3 and
anti-CD28 antibodies. Expression of CD69 was measured by ﬂow
cytometry 24 h following stimulation in CD8 and CD4 T cells. Healthy
(*); melanoma ( ).
Found at doi:10.1371/journal.pmed.0040176.sg006 (4.0 MB TIF).
Figure S7. Scatter Plots to Show Percentage of CD8 and CD4 T Cells
Expressing CD25 24 Hours after Stimulation
Lymphocytes from IFN-low-response melanoma patients and healthy
donors were stimulated with beads coated with anti-CD3 and anti-
CD28 antibodies. Expression of CD25 was measured by ﬂow
cytometry 24 h after stimulation in CD8 and CD4 T cells. Healthy
(*); melanoma ( ).
Found at doi:10.1371/journal.pmed.0040176.sg007 (3.7 MB TIF).
Figure S8. Scatter Plots to Show Percentage of CD8 and CD4 T Cells
Expressing CD71 Six Hours after Stimulation
Lymphocytes from IFN-low-response melanoma patients and healthy
donors were stimulated with beads coated with anti-CD3 and anti-
CD28 antibodies. Expression of CD71 was measured by ﬂow
cytometry 24 h after stimulation in CD8 and CD4 T cells. Healthy
(*); melanoma ( ).
Found at doi:10.1371/journal.pmed.0040176.sg008 (2.2 MB TIF).
Figure S9. Scatter Plots to Show Percentage of CD8 and CD4 T Cells
Expressing IL-2, TNF-a, and IFN-c and Percentage Survival of CD8
and CD4 T Cells after Stimulation
Lymphocytes from IFN-low-response patients and healthy donors
were stimulated with beads coated with anti-CD3 and anti-CD28
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was measured 24 h after stimulation. The percentage survival
(Annexin V-negative 7-AAD-negative cells) was measured by ﬂow
cytometry four days after stimulation. Healthy (*); melanoma ( ).
Found at doi:10.1371/journal.pmed.0040176.sg009 (2.7 MB TIF).
Table S1. Sequences of Primers for Real-Time Quantitative PCR
Found at doi:10.1371/journal.pmed.0040176.st001 (42 KB DOC).
Table S2. Real-Time Quantitative PCR Analysis Comparing Patients
with Melanoma (M) to Healthy Controls (H) for Expression Differ-
ences in CD56dim NK Cells of ISGs and Top-Ranking Genes from
Microarray Analysis
QPCR was used to measure expression of ISGs and top ranked genes
shown by microarray analysis to be differentially expressed in
melanoma versus healthy samples. The Wilcoxon rank sum test
(two-sided) was used to calculate the p-values. The estimated log2 fold
differences (H/M) between healthy and melanoma with 95%
conﬁdence intervals and estimated fold differences (H/M) are shown.
The number of healthy and melanoma samples analyzed is indicated.
Found at doi:10.1371/journal.pmed.0040176.st002 (40 KB DOC).
Accession Numbers
The Gene Expression Omnibus (GEO [http://www.ncbi.nlm.nih.gov/
geo]) accession number for microarray data from this study is
GSE6887. The Entrez Gene accession numbers for the genes discussed
in this paper are shown in parentheses: IFIT3 (3437), RSAD2 (91543),
LOC129607 (129607), IFI44L (10964), IFIT1 (3434), IFIT2 (3433), OAS3
(4940), FREQ (23413), OAS1 (4938), STAT1 (6772), IFI44 (10561), ISG15
(9636), SAMD9L (219285), PARP9 (83666), CXCL11 (6373), GBP1
(2633), CXCL10 (3627), MX2 (4600), EIF2AK2 (5610), LAMP3 (27074),
USP18 (11274), SAMD9 (54809), PLSCR1 (5359), BIRC4BP (54739),
IFI27 (3429), MX1 (4599), HERC5 (51191), CARD9 (64170), CXCL3
(2921), LMO2 (4005), MARCKS (4082), C15orf48 (84419).
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Background. The immune system, in addition to fighting infections,
provides one of the body’s main defenses against cancer. During cancer
development, normal cells acquire genetic changes that allow them to
grow uncontrollably and to move around the body. Some of these
changes alter the antigens (proteins recognized by the immune system)
expressed on their surface. As a result, the immune system recognizes
and eliminates the newly formed cancer cells. Tumors—large masses of
cancer cells—occur when this immune surveillance fails. Some tumors,
for example, hide from the immune system by altering the antigens they
express. Others release factors that shut off the immune response.
However, for many tumor types, it is not clear why immune surveillance
fails during their development or why global immune suppression
develops in most patients with advanced disease.
Why Was This Study Done? Scientists want to understand the
molecular basis of immune dysfunction in patients with cancer because
if they knew what had gone wrong with the immune system, they might
be able to repair it. Also, there is considerable interest in immunotherapy
for cancer—for example, treatment with interferons (proteins made by
certain immune system cells that activate other immune cells and also
kill tumor cells) and the development of vaccines to stimulate antitumor
immune responses. So far, immunotherapy has not been very successful,
probably because of the underlying dysfunction of the immune system
in patients with cancer. Understanding this dysfunction might lead to
improvements in immunotherapy, so in this study the researchers have
investigated the molecular mechanism responsible for immune dysfunc-
tion in patients with metastatic melanoma, a deadly form of skin cancer.
What Did the Researchers Do and Find? The researchers purified
lymphocytes (immune cells that are involved in antitumor responses)
from the blood of patients with metastatic melanoma and healthy
people and examined their patterns of gene expression using a
technique called microarray expression profiling. CD8 T cells (which kill
cells expressing foreign or altered antigens), CD4 T cells (which help
other T and B lymphocytes do their jobs), and B cells (which make
antibodies, proteins that recognize antigens and label cancer cells for
destruction by the immune system) from patients with melanoma all
expressed lower levels of 24 genes, and higher levels of one gene, than
those from healthy individuals. 17 of these genes were interferon-
stimulated genes, which encode proteins responsible for the effects of
interferons. Therefore, the researchers checked the functional responses
of patient and control lymphocytes to interferon. When interferon binds
to lymphocytes, it triggers the addition of a phosphate group to the
protein STAT1, which then induces changes in gene expression. STAT1
phosphorylation occurred in a lower percentage of patient lymphocytes
than control lymphocytes in response to interferon-a (which is some-
times used to treat melanoma). The lymphocytes from one-third of the
patients responded well to interferon-a, but those from the other
patients showed little response. Furthermore, prolonged treatment with
high concentrations of interferon-a partly overcame the defect in
interferon signaling in patient lymphocytes. Finally, T cells from the
patients failed to make the normal markers of immune cell activation or
cytokines (proteins that mediate the killing of tumor cells) after exposure
to activating stimuli and had reduced survival compared to control
lymphocytes.
What Do These Findings Mean? These results indicate that for patients
with metastatic melanoma defects in interferon signaling are an
important contributor to immune dysfunction. They also show that T
cells from patients with melanoma (particularly those who respond
poorly to interferon-a) have functional abnormalities that make them
less likely to recognize and deal with melanoma cells. These results need
confirming in many more patients, but they nevertheless represent an
important step toward understanding the immune dysfunction asso-
ciated with advanced melanoma and possibly other tumors. In addition,
the identification of two subgroups of patients—interferon responders
and poor interferon responders—may explain why only some patients
with melanoma benefit from treatment with interferon-a. It might,
therefore, be possible to pre-select those who would benefit from this
treatment (which has some serious side effects) by examining patient
lymphocytes for interferon responsiveness.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040176.
  US National Cancer Institute information (in English and Spanish) for
patients on the immune system and its involvement in cancer, and for
patients and professionals on melanoma
  American Cancer Society information for patients on immunotherapy
  Cancer Research Institute (New York) web-based book on cancer and
the immune system
  MedlinePlus encyclopedia pages on melanoma (in English and
Spanish)
  Cancer Research UK patient information on melanoma, including
information on immunotherapy
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